Peripheral T cell lymphoma

WikiDoc Resources for Peripheral T cell lymphoma
Articles
Most recent articles on Peripheral T cell lymphoma Most cited articles on Peripheral T cell lymphoma Review articles on Peripheral T cell lymphoma Articles on Peripheral T cell lymphoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Peripheral T cell lymphoma Images of Peripheral T cell lymphoma Photos of Peripheral T cell lymphoma Podcasts & MP3s on Peripheral T cell lymphoma Videos on Peripheral T cell lymphoma
Evidence Based Medicine
Cochrane Collaboration on Peripheral T cell lymphoma Bandolier on Peripheral T cell lymphoma TRIP on Peripheral T cell lymphoma
Clinical Trials
Ongoing Trials on Peripheral T cell lymphoma at Clinical Trials.gov Trial results on Peripheral T cell lymphoma Clinical Trials on Peripheral T cell lymphoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Peripheral T cell lymphoma NICE Guidance on Peripheral T cell lymphoma NHS PRODIGY Guidance FDA on Peripheral T cell lymphoma CDC on Peripheral T cell lymphoma
Books
Books on Peripheral T cell lymphoma
News
Peripheral T cell lymphoma in the news Be alerted to news on Peripheral T cell lymphoma News trends on Peripheral T cell lymphoma
Commentary
Blogs on Peripheral T cell lymphoma
Definitions
Definitions of Peripheral T cell lymphoma
Patient Resources / Community
Patient resources on Peripheral T cell lymphoma Discussion groups on Peripheral T cell lymphoma Patient Handouts on Peripheral T cell lymphoma Directions to Hospitals Treating Peripheral T cell lymphoma Risk calculators and risk factors for Peripheral T cell lymphoma
Healthcare Provider Resources
Symptoms of Peripheral T cell lymphoma Causes & Risk Factors for Peripheral T cell lymphoma Diagnostic studies for Peripheral T cell lymphoma Treatment of Peripheral T cell lymphoma
Continuing Medical Education (CME)
CME Programs on Peripheral T cell lymphoma
International
Peripheral T cell lymphoma en Espanol Peripheral T cell lymphoma en Francais
Business
Peripheral T cell lymphoma in the Marketplace Patents on Peripheral T cell lymphoma
Experimental / Informatics
List of terms related to Peripheral T cell lymphoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The peripheral T-cell lymphomas (PTCLs) consists of a heterogeneous group of aggressive diseases that constitutes ~10%-15% of non Hodgkin lymphoma. The incidence has been estimated to be <1 case per 100,000 of ppl in United states. The most common type is Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), followed by Anaplastic large cell lymphoma, primary systemic type (ALCL) , Angioimmunoblastic T cell lymphoma (AITL) and Extranodal NK/T cell lymphoma, nasal type (PTCLs ), which is the rarest type. Although each type presents differently and has special histological features, they all have similar treatment . In addition, all the types have been associated with poor prognosis. The most common presentation is generalized lymphadenopathy with or without extra nodal manifestations.

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].